Poster

Phase 1 Trial of ADCT-602, a CD22 Targeting ADC Bound to PBD Toxin in Adult Patients With RR CD22+ B-Cell ALL

Email this document.

Enter your email address below to send this document.

PLACEHOLDER START

[ninja_form id=1]

Important Notice

I am a Healthcare Professional registered to practice in the U.S.
I am a U.S. Patient or Caregiver
in footer
MENU